Strengthening research, technological development and innovation
Promoting innovation capacities for a more competitive area
New Immuno-Cluster. Pilot project to improve quality and life expectancy of women with Triple Negative Breast Carcinoma (TNBC) focused on HybriCure® immunoibridioma (Celica), bioreactors (VivaBioCell, NANT) for automated production, innivative SMEs , hospitals / Lead User. Immuno-Cluster creates a system of common resources (qualified personnel, know-how) among project partners and local private and public actors for TNBC therapy improving the quality and life expectancy of women in the area (at the moment, there are no satisfactory treatments).
Autologous immuno-hybridoma have been applied to treat prostate cancer resistant castration revealing that this approach is a safe, non-toxic significant immunity response to significantly prolong the time to secondary therapy. The aim of the project is to create a Cross-border Immuno-Cluster through a clinical experimentation for the treatment of the triple negative breast carcinoma, an aggressive cancer not yet treatable, by an autologous vaccine of cellular immunohybridoma, whose production will be made scalable to meet product needs. The project will be an excellence to put together cutting-edge hospitals, pharmaceutical and biotechnology companies, universities and research centers, which are all relevant European and global players. Activities of partners will be synchronized, bringing them together in an innovative approach with a strong impact in immunotherapy breast cancer clinic. Project partners will achieve two parallel objectives: a) introduce a safe and effective approach to treat triple negative breast cancer (clinical protocol) still missing today, and b) develop a set of common goods (qualified personnel, infrastructure, know-how) on which hospitals, universities, SMEs, start-ups and investors will be able to build their own offers.
The results expected by "Immuno-Cluster" are the following:
· "Number of enterprises cooperating with research institutes": 5 research institutes participating in the clinical research cross-border project (Onkoloski Center Ljubljana, OB Valdoltra, Ospedale dell’Angelo Venice, University of Udine / Department di Area Medica together with ASUIUD - Integrated University Hospital of Udine), will collaborate with 2 private companies (Celica Biomedical, Ljubljana and VivaBioCell, Udine). The PAs are added to the PP with the aim of adding 5 more research institutions.
· "Number of innovative services, products and tools transferred to businesses". 8 companies: 2 Partner companies (Celica Biomedical, Ljubljana and VivaBioCell, Udine) and at least 6 other SMEs supplying innovative products and services, thanks also to the involvement of PA BioHighTechNet (37 companies), SIS-EGIZ.
· “Cross-border innovation clusters in key sectors”: launch of 1 Immuno-Cluster specializing in advanced immunotherapy
. Involve the interest of 5 investors, venture capitalists, businesses, business associations, networks of institutional and informal investors, thanks also to the support by the PA BioValley Investments-Trieste and its financial partners of the PA SIS-EGIZ, Ljubljana.
Lead Partner
Project partner 1
Project partner 2
Project partner 3
Project partner 4
Project partner 5
KEY PROJECT OBJECTIVES
New Immuno-Cluster. Pilot project to improve quality and life expectancy of women with Triple Negative Breast Carcinoma (TNBC) focused on
HybriCure® immunoibridioma (Celica), bioreactors (VivaBioCell, NANT) for automated production, innivative SMEs , hospitals / Lead User. Immuno-Cluster creates a system of common resources (qualified personnel, know-how) among project partners and local private and public actors for TNBC therapy improving the quality and life expectancy of women in the area (at the moment, there are no satisfactory treatments).
CURRENT STATUS OF IMPLEMENTATION
The Project started on 1/1/2020.
Operation co-funded by the European Regional Development Fund
